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Prognosis in lung cancer, one of the commonest cancers in the developed world, is 
poor, with less than 13% of all lung cancer patients surviving more than 5 years after 
diagnosis. With such an elevated mortality rate, it is important to elucidate the 
genetic changes involved in the pathogenesis of lung cancer. 
The process of carcinogenesis can be divided into the three stages of initiation, 
promotion and progression based on evidence mainly from experimental models. 
Such processes have been studied indirectly in humans by measurements of age-
dependent cancer incidence. The development of cancer requires multiple genetic 
alterations, each assumed to consist of the activation of an oncogene or the 
inactivation of a tumor-suppressor gene that is able to disrupt strictly controlled 
cellular processes such as differentiation and growth (1,2). 
Lung cancer, although second to prostate cancer In terms of frequency, is clearly 
the number one cause of cancer deaths among both males and females. Lung 
tumors are carcinomas originating from the respiratory epithelium and are classified 
on the basis of histological type. The two main types are small cell lung cancer 
(SCLC) with few subtypes and non-small cell lung cancer (NSCLC) with a large 
number of subtypes. SCLC most probably arises from pulmonary neuroendocrine 
(NE) cells and accounts for about 25% of all lung tumors. It is an extremely 
aggressive neoplasm, is frequently associated with distant metastases and has the 
poorest prognosis of all lung tumors. NSCLC usually lacks the neuroendocrine 
features that characterise the SCLC tumors and is classified according to Its cell of 
origin. The NSCLCs include: squamous cell carcinomas which may originate from a 
metastatic squamous epithelium; adenocarcinomas which arise in the major bronchi; 
and large cell carcinomas which are predominantly undifferentiated tumors some of 
which may represent their basal or stem cell origin. NSCLC is treated primarily with 
surgery and radiotherapy while SCLC with chemotherapy (3). 
The conversion of normal lung stem cells to malignant ones involves a series of 
changes in different sets of genes (oncogenes and onco-suppressor genes). Such a 
series of events has been demonstrated in colorectal carcinoma by Fearon and 
Vogelstein (4). 
Although in lung cancer the sequential events are not yet established, data from 
different laboratories have focused on the:-chromosomes, oncogenes and onco-
suppressor genes. 
Several studies have shown alterations in chromosomes 1, 3, 6, 7, 8, 11, 13, 15, 17 
and 19 by RFLP analysis. The most frequent changes are deletions in the region 
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p21.3 of chromosome 3 in both NSCLC and SCLC. This region is believed to encode 
a yet unknown onco-suppressor gene (5,6). 
Type I growth factor receptors. This group of molecules include three 
transmembrane glycoprotein (c-erbEM, c-erbQ-2 and c-erbB-3) related sequences 
and intrinsic tyrosine kinase activity. It has been shown that c-eroB-1 and c-eroB-2 
are commonly overexpressed in NSCLC. Overexpression of c-eröB-1 (EGF-r) is 
frequently a result of c-erbB-1 gene amplification (7-9). 
ras gene family. Members of the ras family of proto-oncogenes, comprised of K-ras. 
Η-ras and N-ras, are inner plasma membrane associated GTPases that bind GTP 
cleaving it to GDP. They are involved in signal transduction. Activated ras 
oncogenes, by point mutations in codons 12, 13 and 61 have frequently been 
detected in NSCLC. There is evidence linking mutations in each member of the ras 
family with poor prognosis. K-ras is mutated in 3 0 % of adenocarcinomas and there is 
a correlation with smoking history with about 30% of smokers compared with 2% of 
non-smokers having G-T transversions at codon 12. This type of mutation is 
consistent with exposure of the lung to carcinogens in tobacco smoke such as -
benzo[a]pyrene (10,11). 
myc. The myc gene family encodes at least three proteins c-MYC, N-MYC and L· 
MYC of MW 62-68 kDa. Gene amplification and overexpession of the myc family has 
been shown to be an important feature oî SCLC. It has been postulated that myc 
amplification occurs more frequently* in patients who have undergone 
chemotherapy. Amplification of the c-mycgene is found in about 10% and increased 
expression in about 50% of NSCLCs of all types (12-14). 
c-raf'1. The Q-raf proto-oncogene located in chromosome 3p 14-25 encodes a serine/ 
threonine specific protein kinase, p74 'which is located on the inner plasma 
membrane. Molecular analyses have shown 45% loss of heterozygocity in SCLCs 
(1). J 
c-fos, c-jun, c-fos and c-jun oncogenes form a complex, AP-1, which acts as a 
transcriptional factor. Recent reports show an increased AP-1 activity in NSCLC. As 
there is evidence that AP-1 may be involved in signal transduction, elevated levels 
may be oncogenic. 
c-myb. This proto-oncogene is located on chromosome 6q24 and encodes a nuclear 
transactivator. Recent studies in NSCLC show that aberrant c-myb expression. 
either deletions or defect RNA transcription, may play a role in lung carcinogenesis 
0)· 
p53. The p53 is located in the 17q13 chromosome and encodes a 393bp protein 
which structurally resembles a transcriptional activator factor. p53 functions as a 
negative regulator of cell growth and may play an important role in genomic stability 
and DNA repair. Loss of wild type p53^unctions either by mutation, complex 
formation with viral products or cellular negative regulator(s) such as the mdm2 
gene product, or alteration in subcellular localisation removes an important tumor 
suppressor mechanism and promotes tumorigenesls. 
Mutations in p53 are the commonest genetic changes detected in several different 
types of cancers and are a common feature of NSCLCs. The frequency varies with 
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the type of pulmonary cancer with about 67% of 5q CLCs and 3 7 % of 
adenocarcinomas. p53 mutations carrying G:C-->T:A transversions are found in 
about 50% of NSCLCs. This type of mutation may be caused by benzo[a]pyrene a 
potent mutagen found in tobacco known to cause transversions of this kind. 
Mutations of the p53 are present in over 75% of the SCLC cases. p53 alterations 
have been observed in primary tumors as well as in metastases suggesting its early 
role in the pathogenesis of SCLC (15-17). 
RB. The Rb-1 protein product, pRB, is a DNA binding protein of 110 kDa that is 
thought to be related to events crucial to cell division, The cloning and 
characterisation of the Rb1 gene showed that the loss of the gene or its protein 
product by homozygous deletion or mutation was the event that resulted during 
development, 
There is evidence that the survivors of hereditary retinoblastoma are at higher risk 
for developing lung tumors and to develop them at an earlier age than the general 
population. Relatives of retinoblastoma patients who are carriers of an RB-1 
mutation have a 15-fold increased risk of lung cancer compared to the general 
population (18). 
Regadless of the tissue or origin, the development of a cancer cell from a normal cell 
involves a series of genetic changes that contribute to a loss of normal growth 
control mechanisms. For lung cancer these events are still poorly understood. 
Significant progress has been made recently in determining the status of 
oncogenes such as p53 whose role is considered to be important In the multistep 
process of carcinogenesis. 
It is obvious that further detailed studies are required in order to correlate mutations 
with factors such as diagnosis, clinical'parameters, genetic predisposition and 
prognosis. 
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